奈达铂联合长春瑞滨治疗非小细胞肺癌的临床观察

Combination of nedaplatin and vinorelbine for treatment of non-small cell lung cancer clinical research

目的:观察国产奈达铂(NDP)联合长春瑞滨(NVB)治疗晚期非小细胞肺癌(NSCLC)的临床疗效及不良反应。方法:46例经病理组织学或细胞学确诊的晚期NSCLC,随机分成观察组和对照组。观察组采用NDP80mg/m2,静滴,d1;NVB25mg/m2,静滴,d1、d8。对照组采用顺铂80mg/m2,静滴(联合水化),平均分在连续3d内使用;NVB25mg/m2,静滴,d1、d8。两个方案均为28天为1个周期。按照WHO标准进行评价。结果:46例均可评价疗效,观察组25例,其中3例CR,5例PR,10例SD,7例PD,有效率(RR)为32.0%(8/25);对照组21例,1例CR,4例PR,8例SD,8例PD,RR为23.8%(5/21),两组有效率的差异无统计学意义(P>0.05)。骨髓抑制是主要不良反应,发生率均较高,但两组间差异无统计学意义。除了对照组呕吐的发生率明显高于观察组外(P<0.05),两组的其他不良反应相近(P>0.05)。结论:国产NDP联合NVB方案治疗晚期NSCLC疗效较好,胃肠道反应小,病人耐受好。

Objective：To observe the efficacy and the side effects of nedaplatin in treatment of advanced non-small cell lung cancer （NSCLC）. Methods：The patients with NSCLC by pathologic diagnosis were randomized to two groups： The observed group was treated with nedaplatin （80mg/m^2, iv, d1 ） plus vinorelbine （NVB 25mg/m^2, iv, d1, d8, every 4 weeks）, And the control group was treated with capsulation （ DDP, 80mg/m^2, iv, d1 , or 30mg/m^2, iv, d1 - d3 ） plus vinorelbine （ NVB 25mg/m^2, iv, d1 , d8, every 4 weeks）. Results：25 patients were in the observed group and 21 patients were in the control group, the response rates were 32.0% and 23.8%, respectively. The two groups had similar incidence rate of anemia, neutropenia and thrombocytopenia. But the incidence rate of vomiting was higher in the control group than that in the observed group （P 〈 0. 05 ）. Conclusion：Nedaplatin combined with vinorelbine is an effective and well tolerable regimen in the treatment of advanced NSCLC.